Matrix metalloproteinases and adamalisyns in pathomechanism of pemphigoid;Metaloproteinazy i adamalizyny w patomechanizmie pemfigoidu

Postepy Dermatologii I Alergologii

Volumn 22, Issue 6, 2005, Pages 283-287

  Zebrowska, Agnieszka ^a   Bogdańska, Magdalena ^a   Waszczykowska, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adamalisyns; Metalloproteinases; Pemphigoid; Tissue inhibitors of metalloproteinases

Indexed keywords

ADAMALISYNS; GELATINASE A; GELATINASE B; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ARTICLE; BLISTER; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; IMMUNOPATHOGENESIS; PEMPHIGOID; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 30844437281     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Nagase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
2. Creemers EE, Cleutjens JP, Smits JF, et al.: Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89: 201-10.
3. Zebrowski M, Kierus-Gudaj A, Zebrowska A: Udział metaloproteinaz w patomechanizmach choroby niedokrwiennej serca. Forum Kardiologów 2003; 8: 53-7.
4. Fini ME, Cook JR, Mohan R, et al.: Regulation of matrix metalloproteinase gene expression. In: Matrix metalloproteinases. Parks W, Mehan R (eds). Academic Press, San Diego, 1998: 300-56.
5. Pauschinger M, Chandrasekharan K, Li J, et al.: Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy. Herz 2002; 27: 677-82.
6. Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-60.
7. Reynolds JJ: Connective tissue degradation in health and periodontal disease and the roles of metalloproteinases and their natural inhibitors. Adv Dent Res 1994; 8: 312-9.
8. Gur P, Kaushal S, Shah V: The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. J Clin Invest 2000; 105: 1335-7.
9. Baumann G, Frank SJ: Metalloproteinases and the modulation of GH signaling. J Endocrinol 2002; 174: 361-8.
10. Schlondorff J, Blobel CP: Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J Cell Sci 1999; 112: 3603-17.
11. Leco K, Khokha R, Pavloff N, et al. Tissue inhibitor of matrix metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expresion in mouse cells and tissues. J Biol Chem 1994; 269: 9352-60.
12. Goldring MB: The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000; 43: 1916-26.
13. Goldring MB: The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999; 40: 1-11.
14. Airola K, Ahonen M, Johansson N, et al.: Human TIMP-3 is expressed during fatal development, hair growth cycle and cancer progression. J Histochem Cytochem 1998; 46: 437-47.
15. Reynolds JJ, Meikle MC: The funcional blance of metalloproteinases and inhibitors in tissue degradation: relevance to oral pathologies. J R Coll Surg Edinb 1997; 42: 154-60.
16. Nip LH: Inhibition of epithelial cell matrix metalloproteinases by tetracyclines. J Periodontal Res 1993; 28: 379-85.
17. Wahl LM, Corcoran ML: Regulation of monocyte/macrophage metalloproteinase production by cytokines. J Periodontol 1993; 64 (5 suppl.): 467-73.
18. Schmidt E, Reimer S, Kruse N, et al.: Autoantibodies to BP 180 associated with bullous pemphigoid relase interleukin-6 and interleukin-8 from cultured human keratynocytes. J Invest Dermatol 2000; 115: 842-8.
19. Grando SA, Glukhenky BT, Drannik GN, et al.: Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1989; 125: 925-30.
20. Saarialho-Kere UK, Vaalamo M, Airola K, et al.: Interstitial collagenase is expressed by keratinocytes that are actively involved in reepithelialization in blistering skin disease. J Invest Dermatol 1995; 104: 982-8.
21. Oikarinen A, Kylmaniemi M, Autio-Harmainen H, et al.: Demonstration of 72-kDa and 92-kDa forms of type IV collagenase in human skin: variable expression in various blistering diseases, induction during re-epithelialization, and decrease by topical glucocorticoids. J Invest Dermatol 1993; 101: 205-10.
22. Welgus HG, Bauer EA, Stricklin GP: Elevated levels of human collagenase inhibitor in blister fluids of diverse etiology. J Invest Dermatol 1986; 87: 592-6.
23. Oikarinen AI, Zone JJ, Ahmed AR, et al.: Demonstration of collagenase and elastase activities in the blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid. J Invest Dermatol 1983; 81: 261-6.
24. Verraes S, Hornebeck W, Polette M, et al.: Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 2001; 117: 1091-6.
25. Franzke CW, Tasanen K, Schacke H, et al.: Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J 2002; 21: 5026-35.
26. Schaecke H, Schumann H: Two Forms of Collagen XVII in Keratinocytes a full-length transmembrane protein and soluble ectodomain. J Biol Chem 1998; 273: 25937-43.
27. Yoshiaki H, Jiro U: Cleavage of BP180, a 180-kDa Bullous Pemphigoid Antigen, Yields a 120-kDa Collagenous Extracellular Polypeptide. J Biol Chem 1998; 273: 9711-7.
28. Claus-Werner F, Kaisa T. Shedding of Collagen XVII/BP180. J Biol Chem 2004; 279: 24521-9.
29. Schumann H, Baetge J, Tasanen K, et al.: The shed ectodomain of collagen XVII/BP180 is targed by autoantibodies in different blistering skin diseases. AM J Pathol 2000; 156: 685-95.
30. Tasanen K, Tunggal L: Keratinocytes from patient lacking collagen XVII display a migratory phenotype. AM J Path 2004; 164: 2027-38.